Cellid Co., Ltd.
Develops immunotherapeutic vaccines for cancer and infectious diseases.
299660 | KO
Overview
Corporate Details
- ISIN(s):
- KR7299660001
- LEI:
- Country:
- South Korea
- Address:
- 서울시 관악구 관악로 1 서울대학교 142동 5층, 서울시
- Website:
- http://www.cellid.co.kr
- Sector:
- Manufacturing
Description
Cellid Co., Ltd. is a research and development biotechnology company focused on immunotherapeutic vaccines. The company's activities are centered on two proprietary technology platforms: CeliVax for anti-cancer immunotherapy and an adenovirus vector platform for infectious disease vaccines. The CeliVax platform is used to develop personalized vaccines that utilize a patient's own B cells and monocytes to target specific cancer antigens. The adenovirus vector platform enables the rapid development of safe, non-replicating viral vector vaccines, with a key application being its COVID-19 vaccine candidate. Cellid's pipeline is built upon these core technologies to address unmet medical needs in oncology and virology.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-07-07 00:00 |
타인에대한담보제공결정
|
Korean | 20.1 KB | ||
| 2023-06-30 00:00 |
[기재정정]증권신고서(지분증권) (2023.08)
|
Korean | 2.1 MB | ||
| 2023-06-16 00:00 |
[기재정정]주식매수선택권부여에관한신고
|
Korean | 22.8 KB | ||
| 2023-06-16 00:00 |
[기재정정]주식매수선택권부여에관한신고
|
Korean | 24.9 KB | ||
| 2023-06-16 00:00 |
주요사항보고서(유상증자결정)
|
Korean | 23.4 KB | ||
| 2023-06-16 00:00 |
증권신고서(지분증권) (2023.08)
|
Korean | 1.7 MB | ||
| 2023-05-23 00:00 |
투자판단관련주요경영사항(임상시험계획승인신청)(COVID-19 예방 백신 AdCLD-CoV19-1 OMI의 제3상 임상시험 계획(IND) 신청)
|
Korean | 8.5 KB | ||
| 2023-05-15 00:00 |
분기보고서 (2023.03)
|
Korean | 887.4 KB | ||
| 2023-05-08 00:00 |
기타경영사항(자율공시)(국책과제 선정(아데노바이러스 벡터 플랫폼 기반 COVID-19 변이에 대한 다가백신 개발))
|
Korean | 8.1 KB | ||
| 2023-04-05 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 22.3 KB | ||
| 2023-04-05 00:00 |
주식등의대량보유상황보고서(일반)
|
Korean | 133.3 KB | ||
| 2023-03-29 00:00 |
정기주주총회결과
|
Korean | 26.4 KB | ||
| 2023-03-27 00:00 |
투자판단관련주요경영사항(코로나바이러스감염증-19(COVID-19) 예방 백신 AdCLD-CoV19 제1/2a상 임상시험 결과)
|
Korean | 23.0 KB | ||
| 2023-03-24 00:00 |
주식등의대량보유상황보고서(약식)
|
Korean | 67.9 KB | ||
| 2023-03-21 00:00 |
투자판단관련주요경영사항(코로나바이러스감염증-19(COVID-19) 예방 백신 AdCLD-CoV19-1 제1상 임상시험 결과)
|
Korean | 19.0 KB |
Automate Your Workflow. Get a real-time feed of all Cellid Co., Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cellid Co., Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cellid Co., Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
